Mannose coated Rifampicin-Curcumin-nanomicelles against Mycobacterium tuberculosis

GALDOPORPORA JUAN; RIEDEL JENNIFER; FUENTES PEDRO; JUAN MARTINEZ; PALMAS LUCIA; MANCONI MARIA; MARIANA GARCES; MARTINENA MARTINA; BERNABEU EZEQUIEL; EVELSON PABLO; CHIAPPETTA, DIEGO; TATEOSIAN NANCY; MORETTON MARCELA

Congreso; 6ta Reunión Internacional de Ciencias Farmacéuticas (RICiFa 2020+1); 2021

Tuberculosis (TB) is one of leading causes of death from a single infectiuos agent. Rifampicin is one of the most effective first-line anti-TB drug and curcumin is an antioxidant agent that has been studied to minimize oxidative stress in anti-TB therapy. In the present work a novel nanocarrier loaded with rifampicin and curcumin for TB treatment was prepared. Soluplus micelles were prepared by aqueous copolymer dispersion and drug loading was performed by organic solvent diffusion technique. Micelles were coated with mannose and characterized by FT-IR and RAMAN spectroscopy. Micellar size distribution were determined using DLS and the antioxidant activity was measured by DPPH and ABTS methods. Moreover, in vitro microbicidal activity was determined in THP-1 derivated macrophagues infected with M. tuberculosis (MtbH37Rv). Optimal system conditions were achieved, Soluplus 10%, Rifampicin:Curcumin weight ratio 2:1. After drug encapsulation and lyophilization, systems exhibited unimodal size distribution (Dh ~ 108 nm) and they demonstrated in vitro antioxidant activity (~62% DDPH and 41% ABTS inhibition). Finally, mannose and curcumin incorporation to the rifampicin-loaded nanoformulation improved its in vitro antimicrobial activity against Mtb over 24 h. Hence, this attractive nanotechnological platform demonstrated its potential as a novel nanoformulation for an optimize anti-TB therapy due to its antioxidant and antimicrobial properties